The goal of reaching functional cure rates of up to 30% in hepatitis B now looks realistic, and Vir and GSK and others are racing to find the best combinations of novel and existing treatment options - new results at EASL this week will show how they are faring.
Vir Biotechnology is aiming to bring a functional cure to as many as 30% of chronic hepatitis B (HBV) patients via novel drug combinations, and will be looking for its Phase II data to give it an edge on GSK, its main rivals..
The company will have multiple data presentations of its siRNA-based VIR-2218 and monoclonal antibody candidate VIR-3434 at the European Association...
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
